C12N 2710/16162
By genetic engineering
Official title: by genetic engineering
C12N2710/16162 (By genetic engineering) appears on 30 US grants and 33 published applications in this corpus.
Search patents in C12N- Granted patents
- 30
- Published applications
- 33
- Assignees
- 22
- Inventors
- 48
- Latest grant
- 28 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 2 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 1 |
| 2008 | 0 | 2 |
| 2009 | 3 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 5 |
| 2014 | 1 | 3 |
| 2015 | 1 | 2 |
| 2016 | 3 | 2 |
| 2017 | 1 | 4 |
| 2018 | 2 | 2 |
| 2019 | 0 | 2 |
| 2020 | 4 | 5 |
| 2021 | 1 | 0 |
| 2022 | 3 | 1 |
| 2023 | 0 | 1 |
| 2024 | 1 | 0 |
| 2025 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Intrinsic system for viral vector transgene regulation28 Oct 2025US 12,453,765 B2The Vaccine Group Limited
- Modulation of replicative fitness by deoptimization of synonymous codons17 Sep 2024US 12,090,197 B2The Government of the USA, as represented by the Secretary, Department of Health and Human Services
- Modulation of replicative fitness by deoptimization of synonymous codons15 Nov 2022US 11,497,803 B2The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
- Recombinant HCMV and RHCMV vectors and uses thereof8 Mar 2022US 11,266,732 B2Oregon Health & Science University
- Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids8 Mar 2022US 11,268,071 B2Merck Sharp & Dohme Corp.
- Modulation of replicative fitness by deoptimization of synonymous codons31 Aug 2023US 2023/0270833 A1The Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
- Intrinsic system for viral vector transgene regulation30 Jun 2022US 2022/0202925 A1The Vaccine Group Limited
- Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids17 Dec 2020US 2020/0392468 A1Merck Sharp & Dohme Corp.
- Methods and Compositions Useful In Generating Non Canonical CD8+ T Cell Responses17 Dec 2020US 2020/0392534 A1Oregon Health & Science University
- Cmv vectors comprising microrna recognition elements26 Nov 2020US 2020/0368333 A1
Most cited
By later US patents
- Recombinant human cytomegalovirus vaccine22US 5,720,957 AAmerican Cyanamid Company · 1998
- Modulation of replicative fitness by deoptimization of synonymous codons20US 8,846,051 B2The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · 2014
- Recombinant HCMV and RHCMV vectors and uses thereof20US 9,249,427 B2Oregon Health & Science University · 2016
- Recombinant HCMV and RHCMV vectors and uses thereof13US 9,982,241 B2Oregon Health & Science University · 2018
- Cells transformed or transfected with HCMV US2 gene12US 5,908,780 AAmerican Cyanamid Company · 1999